Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 600 participants.

Also called NCT07033585

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose health services research
Phase
Phase 2/3
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair (from the registry)
Registry
  • NCT NCT07033585
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07033585. Randomized; quadruple masking; primary purpose health services research. Start 2026-06-15 (actual); primary completion 2026-10-18 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers
Acronym
GD-T2D
Intervention (Drug)
Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes
Intervention (Drug)
China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair (class: industry)
Collaborator
UnitedHealthcare (class: other)

Record details

Record id
cardio:ct-nct07033585
Content hash
8dfda6747df4bf8ed604bc641169ed20b69d80b022b419298dbe8a0e73e038e7